Introduction
Bladder cancer is the most common malignancy of the urinary tract, accounting for approximately 53 000 new cases and 12 000 deaths each year in the United States (Parker et al., 1996) . The prognosis of patients with advanced bladder cancer is still extremely poor in spite of recent therapeutic advances such as improved surgical techniques and perioperative combination chemotherapy (Thrasher and Crawford, 1993) . It is thus important to investigate the factors that inhibit the therapeutic eects, in order to develop novel treatments and consequently improve the prognosis of patients with advanced bladder cancer.
Cisplatin, a coordination complex of platinum, is one of the most eective chemotherapeutic agents and has been widely used for the treatment of various malignant tumors (Chu, 1994) . For patients with advanced bladder cancer, cisplatin-based combination chemotherapy has been the mainstay of treatment, and it is at least palliatively eective (Sternberg et al., 1993) . However, the ecacy of cisplatin-based combination chemotherapy is limited due to the de novo drug resistance or the development of cellular resistance during treatment; therefore, an increased survival rate cannot always be expected.
Gene transfer techniques may provide new therapeutic approaches to a variety of malignancies (Rousculp et al., 1992; Old®eld et al., 1993) . Among them, replication-de®cient adenoviral vectors have been shown to be attractive because they are capable of ecient infection in target cells and are safe for clinical use (Welsh et al., 1994) . A number of studies have demonstrated that the adenoviral-mediated gene therapy of wild-type p53 in tumor cells suppressed the tumor growth both in vitro and in vivo through the induction of the apoptotic pathway (Fujiwara et al., 1994; Liu et al., 1995; Gomez-Manzano et al., 1996; Hamada et al., 1996; Mujoo et al., 1996) . Although the ecacy of the p53 gene therapy in human bladder cancer has not been studied in detail, it is possible that p53 gene therapy will be a useful therapeutic strategy for advanced human bladder cancer.
The bcl-2 gene, ®rst recognized as the protooncogene translocated to the immunoglobulin heavy chain locus in human follicular B cell lymphomas, is the prototype of a novel class of oncogenes that contributes to neoplastic cell growth not by accelerating the rate of cellular proliferation but rather by enhancing the tumor cell survival through the inhibition of apoptosis (Tsujimoto et al., 1985; McDonnell et al., 1989) . A constitutive overexpression of Bcl-2 protects cells from apoptosis induced by a wide variety of stimuli, such as radiation, chemotherapeutic agents, anti-Fas antibody, hyperthermia and growth factor deprivation (Vaux et al., 1988; Tsujimoto, 1989; Dive and Hickman, 1991; Eliopoulos et al., 1995; Lacronique et al., 1996) . Recent studies demonstrated that Bcl-2 expression closely correlates with the poor prognosis of various human malignant tumors, including bladder cancer (Gallo et al., 1996; King et al., 1996; Bilim et al., 1996) . However, the biological signi®cance of Bcl-2 expression in the resistance to the therapies for human malignancies remains largely unknown.
To clarify the role of Bcl-2 in the treatment of bladder cancer, we transfected bcl-2 cDNA into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. We then examined the ecacies of cisplatin treatment and adenoviralmediated p53 gene (Ad5CMV-p53) transfer in the Bcl-2-expressing KoTCC-1 cell lines both in vitro and in vivo.
Results

Generation of Bcl-2-overexpressing KoTCC-1 cell lines
KoTCC-1 was transfected with the human bcl-2 cDNA expression vector pDR2/bcl-2 or the pDR2 vector alone as a control. After the drug selection, a number of Hygromycin-resistant stable transfectants were developed and then analysed for expression of the Bcl-2 protein by Western blotting. As shown in Figure 1 , variable levels of the Bcl-2 protein were detected in ®ve independent Bcl-2-transfected clones which consisted of one clone expressing a low level of Bcl-2 (KoTCC-1/ BL) and four clones expressing high levels of Bcl-2 (KoTCC-1/BH1 to KoTCC-1/BH4). In contrast, no detectable Bcl-2 protein was expressed in either the parental KoTCC-1 (KoTCC-1/P) or the control vectortransfected cell line (KoTCC-1/C). The four clones expressing high levels of Bcl-2 protein showed the almost same results in the subsequent experiments; therefore, we hereafter report only the data of KoTCC-1/P, KoTCC-1/C, KoTCC-1/BL and KoTCC-1/BH1.
In vitro eects of cisplatin treatment on KoTCC-1 sublines
To determine whether Bcl-2 overexpression confers a proliferative advantage on KoTCC-1, the in vitro growth rates of KoTCC-1/P, KoTCC-1/C, KoTCC-1/ BL and KoTCC-1/BH1 were analysed under the cultured conditions used with serum-free condition medium (DMEM/F-12). There was no signi®cant dierence in cell proliferation among these cell lines (data not shown).
The KoTCC-1 sublines were subsequently examined for their response to cisplatin with the use of an MTT assay. KoTCC-1/BL and KoTCC-1/BH1 acquired resistance to cisplatin in comparison with KoTCC-1/P and KoTCC-1/C (P50.01; Figure 2a ). The concentrations of cisplatin at which a 50% inhibition of cell viability was induced for KoTCC-1/P, KoTCC-1/C, KoTCC-1/BL and KoTCC-1/BH1 were 5.5, 5.9, 11.4 and 12.9 mg ml
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, respectively. The increase in resistance to cisplatin in the Bcl-2 transfectants was examined by an analysis of the cell cycle distribution after the exposure to cisplatin. The KoTCC-1 sublines were treated with cisplatin at a concentration of 10 mg ml 71 for 72 h and then a¯ow cytometric analysis of each cell line stained with propidium iodide (5 mg ml 71 ) was performed. As shown in Figure 2b , about 70% of both KoTCC-1/P and KoTCC-1/C showed DNA degradation characteristic of apoptotic cells. In contrast, the fractions that underwent apoptosis in KoTCC-1/BL and KoTCC-1/ BH1 were only about 40% and 25% respectively (P50.01). Furthermore, we performed DNA fragmentation analysis of each cell line treated with cisplatin under the same condition described above, in order to assess the apoptotic feature more de®nitively. The characteristic apoptotic DNA ladders were observed in KoTCC-1/P and KoTCC-1/C but not in KoTCC-1/BL and KoTCC-1/BH1 (Figure 2c) .
To determine the p53 responses after the treatment with cisplatin at a concentration of 10 mg ml 71 in KoTCC-1 sublines that was shown to exhibit the wild-type p53 status in our preliminary study, the levels of p53 protein accumulation were analysed by Western blotting in lysates from these cell lines at various time points for 72 h. In accordance with the previous studies Jayarman and Prives, 1995) , p53 protein accumulation was also induced in KoTCC-1 sublines in a time-dependent manner. However, these p53 inductions were significantly prolonged and the levels of accumulated p53 were increased in KoTCC-1/BL and KoTCC-1/BH1 compared to KoTCC-1/P and KoTCC-1/C ( Figure  2d ).
In vivo eects of cisplatin treatment on KoTCC-1 sublines
To examine the in vivo eect of Bcl-2 expression on tumor growth, 5610 6 cells of each cell line were injected subcutaneously in the¯ank of Balb/c nu/nu mice. There were no signi®cant dierence in tumor growth among KoTCC-1/P, KoTCC-1/C, KoTCC-1/ BL and KoTCC-1/BH1 (data not shown); that is, the Bcl-2 overexpression did not stimulate a proliferative potential of KoTCC-1 in vivo as well as in vitro.
Bcl-2 β-Tubulin Therapy resistant phenotype induced by Bcl-2 expression H Miyake et al experiment, no tumor-related deaths were observed. We then performed the terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine 5'-triphosphate nick end labeling (TUNEL) staining of the subcutaneous tumors in nude mice 3 days after cisplatin treatment schedule was over, in order to evaluate the apoptotic features of cisplatin-treated tumors. Apoptotic cells were extensively detected in the tumors formed by KoTCC-1/P and KoTCC-1/C, but not in the tumors formed by KoTCC-1/BL and KoTCC-1/BH1 (Figure 3b ). The goal of the present in vivo experiments was to evaluate the biological signi®cance of Bcl-2 expression in the treatment of human bladder cancer. Therefore, we established an intraperitoneal tumor cell implantation model; that is, we used the abdominal cavity as a substitute for the urinary bladder because of their common feature as a closed cavity, and the ecacy of treatment in this model was assessed with the prognosis of mice that received an intraperitoneal injection of tumor cells. Without cisplatin treatment, 100% of the mice injected with 5610 6 cells of any of the cell lines intraperitoneally produced hemorrhagic ascites and died within 15 days. When mice received an intraperitoneal injection of cisplatin (5 mg kg
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) twice a week for 2 weeks 3 days after the implantation of tumor cells, 100% of the mice (5/5) given an injection of KoTCC-1/P or KoTCC-1/C survived for more than 50 days, whereas 40% (2/5) given KoTCC-1/BL and 80% (4/5) given KoTCC-1/BH1 died within 50 days ( Figure 3c ). In this experiment, hemorrhagic ascites were observed in all of the mice that died within 50 days. The prognosis of the KoTCC-1/BH1-injected mice was signi®cantly inferior to those of the KoTCC-1/P and KoTCC-1/C-injected mice (P50.05). However, the prognostic disadvantage of the KoTCC-1/BLinjected mice was not signi®cantly dierent from those of control mice.
In vitro eects of Ad5CMV-p53 transfer on KoTCC-1 sublines To examine the adenoviral transduction eciency of the KoTCC-1 sublines in vitro, each cell line was infected for 48 h with AxCALacZ, an adenovirus that expresses the b-galactosidase gene (100 PFU/cell). After X-gal staining, more than 95% of the cells were found to be infected with AvCALacZ in KoTCC-1/P, KoTCC-1/C, KoTCC-1/BL and KoTCC-1/BH1 (data not shown).
To study the eect of Ad5CMV-p53 on the in vitro growth of the KoTCC-1 sublines, each cell line was infected with various doses of Ad5CMV-p53, and the cell viabilities were quantitated by MTT assay. The anti-proliferative eects of Ad5CMV-p53 on KoTCC-1/BL and KoTCC-1/BH1 were signi®cantly suppressed in comparison with those on KoTCC-1/P and KoTCC-1/C (P50.01; Figure 4a ). In contrast, the adenovirus that contained the luciferase gene and was used as a control in this study, Ad5CMV-Luc, was unable to inhibit the growth of the KoTCC-1 sublines at the same doses as Ad5CMV-p53 (data not shown).
To detect the cell populations undergoing apoptosis in the KoTCC-1 sublines infected with Ad5CMV-p53, a¯ow cytometric analysis was performed. Seventy-two hours after the infection with Ad5CMV-p53 (100 PFU/ cell), each cell line was stained with propidium iodide (5 mg ml
) and the percentage of apoptotic cells was then calculated. As shown in Figure 4b , the DNA degradation characteristic of apoptosis was detected in about 70% of both KoTCC-1/P and KoTCC-1/C, whereas the proportions of cells that underwent apoptosis were only about 30% in KoTCC-1/BL and 10% in KoTCC-1/BH1 (P50.01), respectively. In addition, less than 5% of the KoTCC-1 sublines infected with Ad5CMV-Luc (100 PFU/cell) underwent apoptosis (data not shown). We then performed DNA fragmentation analysis of each cell line treated with Ad5CMV-p53 under the identical condition described in¯ow cytometric analysis. The agarose gel electrophoresis showed the characteristic apoptotic DNA ladder in KoTCC-1/P and KoTCC-1/C but not in KoTCC-1/BL and KoTCC-1/BH1 (Figure 4c) .
To determine the expression of p53 protein in the KoTCC-1 sublines infected with Ad5CMV-p53 (100 PFU/cell), the accumulation levels of p53 protein were monitored every 24 h for 5 days by Western blotting. The expression of p53 protein was observed to take place in a time-dependent manner in each of the KoTCC-1 sublines. However, as seen in the cisplatin treatment experiment, the accumulations of p53 protein in KoTCC-1/BL and KoTCC-1/BH1 were highly detectable for a long period in comparison with those in KoTCC-1/P and KoTCC-1/C; that is, the p53 protein in KoTCC-1/BL and KoTCC-1/BH1 peaked at 48 ± 72 h after the infection and persisted to at least 120 h, whereas in KoTCC-1/P and KoTCC-1/C it peaked at 48 h and persisted to 96 h (Figure 4d ). In addition, no detectable p53 protein was observed in the KoTCC-1 sublines after the infection with Ad5CMV-Luc (100 PFU/cell) (data not shown).
In vivo eects of Ad5CMV-p53 transfer on KoTCC-1 sublines
The eect of Ad5CMV-p53 on the KoTCC-1 sublines in inhibiting tumor growth in vivo was evaluated in tumor-bearing nude mice. After the subcutaneous injection of 5610 6 of each cell line, tumors were allowed to grow for 7 days to a diameter of about 5 mm. The mice then received an intratumoral injection of 300 ml of either Ad5CMV-p53 (2610 7 PFU ml
) twice a week for 2 weeks. The Ad5CMV-p53 injection resulted in the reduction of tumor size formed by the KoTCC-1 sublines, and 40 days after the injection of tumor cells, KoTCC-1/BH1 and KoTCC-1/BL formed tumors about 2 and 1.5 times as large as those as formed by KoTCC-1/P and KoTCC-1/C, respectively (P50.05; Figure 5a ). In contrast, there was no signi®cant dierence in tumor growth among KoTCC-1 sublines after the injection of Ad5CMV-Luc (data not shown). No mice died from the experimental conditions used for the above study. Furthermore, the TUNEL staining performed 3 days after the Ad5CMV-p53 injection schedule showed that Ad5CMV-p53 extensively induced apoptosis in the tumors formed by KoTCC-1/P and KoTCC-1/C, but not in the tumors formed by KoTCC-1/BL and KoTCC-1/BH1 (Figure 5b) .
To address the feasibility of p53 gene therapy for bladder cancer, we examined the ecacy of Ad5CMV- p53 in the KoTCC-1 sublines by using the intraperitoneal tumor cell implantation model as described above to examine the in vivo eects of cisplatin. Mice were intraperitoneally injected with 5610 6 of one of the KoTCC-1 sublines, and 3 days after the implantation of tumor cells, they received an intraperitoneal injection of either 300 ml of Ad5CMV-p53 ) twice a week for 2 weeks. After the injection of Ad5CMV-p53, 80% of the mice (4/5) given injected with KoTCC-1/P and KoTCC-1/C survived for more than 50 days, whereas 60% (3/5) of the mice given KoTCC-1/BL and 100% (5/5) of those given KoTCC-1/BH1 died within 30 days ( 6 cells of each KoTCC-1 subline, and 3 days after the implantation of tumor cells, the mice received an intraperitoneal injectin of 300 ml of Ad5CMV-p53 (2610 7 PFU ml 71 ) twice a week for 2 weeks. The survival of mice was monitored for 60 days. 5 mice/group a c Therapy resistant phenotype induced by Bcl-2 expression H Miyake et al 5c). In this experiment, all of the mice that died had produced hemorrhagic ascots. The prognoses of the mice injected with KoTCC-1/BL and KoTCC-1/BH1 were signi®cantly inferior to those of the mice injected with KoTCC-1/P and KoTCC-1C (KoTCC-1/BL, P50.05; KoTCC-1/BH1, P50.01). Further, all the mice infected with Ad5CMV-Luc died within 18 days irrespective of the cell lines injected.
Discussion
The prognoses of invasive and/or metastatic bladder cancers are still extremely poor in spite of the recent therapeutic advances (Thrasher and Crawford, 1993) ; therefore, there is a pressing need to identify the mechanisms that inhibit the present therapeutic strategies and to develop novel eective treatments.
In the present study, we focused on Bcl-2, which has been known to suppress apoptosis induced by a wide variety of stimuli (Vaux et al., 1988; Tsujimoto, 1989; Dive and Hickman, 1991; Eliopoulos et al., 1995; Lacronique et al., 1996) , and we analysed the eects of cisplatin treatment and Ad5CMV-p53 transfer on Bcl-2 expression in bladder cancer cells. Cisplatin has been the mainstay of treatment for advanced bladder cancer (Sternberg et al., 1993) , and Ad5CMV-p53 may be a novel eective approach to this disease (Werthman et al., 1996) . KoTCC-1, a human bladder transitional cell carcinoma cell line, was established from the ascites of a patient with peritonitis carcinomatosa (Miyake et al., 1997) . Our previous studies demonstrated that KoTCC-1 was transplantable into nude mice after subcutaneous and intraperitoneal injection, and was highly sensitive to some chemotherapeutic agents including cisplatin. Additionally, no detectable Bcl-2 protein was detected in KoTCC-1 by the initial screening of some human bladder cancer cell lines. These features were suitable for the purposes of the present experiments. Accordingly, we introduced human Bcl-2 gene into KoTCC-1, and consequently generated stable KoTCC-1 cell lines expressing variable levels of Bcl-2 protein.
When the KoTCC-1 sublines were treated with cisplatin, we observed a concentration-dependent decrease in cell viability. However, the Bcl-2 low expressor (KoTCC-1/BL) showed a small but definitive decrease in cell viability, and the high Bcl-2 expressor (KoTCC-1/BH1) showed almost sustained survival at the concentration of cisplatin at which the parental KoTCC-1 and the vector-transfected control cell line showed 50% inhibitions of cell viability. Thē ow cytometric analysis and DNA fragmentation analysis also demonstrated that the apoptotic fraction of the cisplatin-treated Bcl-2 expressors were significantly smaller than those of the non-Bcl-2 expressor. As in the in vitro experiments, we observed an obstructive eect of Bcl-2 on cisplatin treatment in both subcutaneous and intraperitoneal tumor cell implantation models. We also performed the TUNEL staining of the implanted tumors and found that the cells undergoing apoptosis were extensively observed in the subcutaneous tumors formed by non-Bcl-2 expressor, but not in the tumors formed by Bcl-2 expressor. Since intraperitoneal tumor cell implantation is a particularly suitable model for observing the clinical course of the tumor progression of bladder cancer, the result of the present experiment is thought to re¯ect the biological eect of Bcl-2 expression on the drug resistance found in the course of clinical chemotherapy. Furthermore, recent studies reported a signi®cant correlation between the Bcl-2 expression in bladder cancer tissues and the poor prognosis of the patients (King et al., 1996; Bilim et al., 1996) . Taken together, these ®ndings strongly suggest that the Bcl-2 expression in the human bladder cancer cells increased the resistance to cisplatin treatment, in part through the inhibition of the apoptotic pathway.
The mechanism by which Bcl-2 expression prolongs and increases the accumulation of p53 in response to cisplatin treatment is of interest. A number of studies have demonstrated that severe mutational DNA damages, which are caused by chemotherapeutic agents including cisplatin, induce transient accumulation of p53 protein and result in programmed cell death (Lowe et al., 1993 (Lowe et al., , 1994 Chu, 1994) . It has also been reported that wild-type p53-triggered apoptosis was inhibited by Bcl-2 (Wang et al., 1993; Chiou et al., 1994) . Taken together, the parental and control KoTCC-1 cells underwent apoptosis by the transient accumulation of p53 in response to cisplatin whereas Bcl-2 prevented the cells from undergoing the p53-induced apoptosis in the Bcl-2-transfected cells. Therefore, it can be speculated that inhibition of apoptosis by Bcl-2 expression maintains the signal for accumulation of p53 protein after the DNA damage and consequently induces high-level and long-term expression of p53 in the Bcl-2-transfected cisplatin resistant cells.
As described above, even cisplatin treatment, which is at present thought to be the most eective therapy for advanced bladder cancer, is not able to produce satisfactory results in Bcl-2-expressing bladder cancer cells. We thus analysed the ecacy of p53 tumor suppresser gene therapy in the KoTCC-1 sublines as a possible new therapeutic approach. In this experiment, we used a replication-de®cient adenoviral vector encoding human wild-type p53 under the control of the human cytomegalovirus promoter (Ad5CMV-p53), which has some useful properties including a highinfectious ability, a short limited period of the transgene expression and a very low probability of integration of the transgene to host genome (Welsh et al., 1994) . A number of studies have demonstrated the potential of wild-type p53 as an agent for cancer gene therapy (Crystal, 1995; Roth et al., 1996) ; however, to our knowledge there seems to be no reports on the molecular mechanism interfering with the eects of its therapy.
As previous studies have demonstrated the growth inhibitory eects of wild-type p53 on lung cancer, head and neck cancer, cervical cancer, glioma and ovarian cancer by using p53-adenoviral vectors (Fujiwara et al., 1994; Liu et al., 1995; Gomez-Manzano et al., 1996; Hamada et al., 1996; Mujoo et al., 1996) , we observed the marked growth inhibition of the parental KoTCC-1 and vector-transfected control cell line after the infection of Ad5CMV-p53 in vitro; the growth inhibitory eects by Ad5CMV-p53 on the Bcl-2-transfected cell lines were signi®cantly suppressed. We also showed by¯ow cytometric analysis that the mechanism of the growth suppression induced by the overexpression of wild-type p53 depends on the apoptotic pathway. Furthermore, as observed after the cisplatin treatment, the accumulation of the p53 protein was highly detectable for a long period in the Bcl-2-transfected cell line in comparison with the control. This phenomenon seemed to be due to the ability of Bcl-2 to block the p53-dependent apoptosis as described above. Thus, if Bcl-2 was overexpressed, the ecacy of the adenoviral-mediated p53 transfer in KoTCC-1 cells in vitro was considerably obstructed through the inhibition of apoptosis.
Our in vivo experiments (i.e., the subcutaneous and intraperitoneal tumor cell implantation models) clearly demonstrated that in spite of the satisfactory eects of the adenoviral-mediated p53 gene therapy on KoTCC-1 cells, the expression of the Bcl-2 protein markedly inhibited its therapeutic eects. The gene therapy in an intraperitoneal tumor cell implantation model demonstrated a marked increase in the survival of mice given an injection of the Bcl-2-transfected cell line compared with that of the control cell line. In addition, both the in vitro and in vivo growth inhibitory eects of the adenoviral-mediated p53 gene therapy were more markedly obstructed than that of the cisplatin treatment, when Bcl-2 was overexpressed in the KoTCC-1 cells. The dierences suggest that DNA damage-induced cell death does not completely depend on the p53-induced apoptotic pathway and that Bcl-2 blocks the p53-dependent apoptosis more eectively than the p53-independent apoptosis. Accordingly, it would be necessary to add some adequate therapies, such as chemotherapy and radiotherapy, if adenovirus p53 vectors are used for the gene therapy of patients with Bcl-2-expressing bladder cancer.
In conclusion, we have demonstrated that the overexpression of Bcl-2 causes an inhibition of apoptosis, resulting in the enhanced resistance potentials to both cisplatin treatment and adenoviralmediated p53 gene therapy for the human bladder cancer cell line KoTCC-1. Although more studies are necessary to explain the problems regarding cisplatin treatment and p53 gene therapy for advanced bladder cancer expressing Bcl-2, our ®ndings strongly suggest that even employing these agents, it may be required to develop another form of treatment to diminish the Bcl-2 expression.
Materials and methods
Tumor cell lines
The human bladder cancer cell line KoTCC-1 was established from the ascites of a patient with peritonitis carcinomatosa in our laboratory (Miyake et al., 1997) . The human renal cell carcinoma cell line ACHN, the human prostate cancer cell line LNCaP and the human glioblastoma cell line U251 MG were obtained from American Type Culture Collection (Rockville, MD). KoTCC-1, LNCaP and U251 MG were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 100 m ml 71 penicillin and 0.1 mg ml 71 streptomycin. The ACHN cells were maintained in MEM supplemented with 10% fetal calf serum, 200 mM glutamine, 100 m ml 71 penicillin and 0.1 mg ml 71 streptomycin. We con®rmed that KoTCC-1 exhibited the wild-type p53 status by a yeast functional assay and DNA sequencing (unpublished observation). The U251 MG cell line has shown to contain a single point mutation at codon 273 in the p53 gene (Kyo et al., 1993) . Previous studies showed that ACHN cells express the Bcl-2 protein, but LNCaP cells do not (Rao et al., 1995; Tomita et al., 1996) ; therefore, we used these cell lines as a positive and negative control, respectively, for the screening of Bcl-2 expression in the KoTCC-1 sublines.
Expression plasmid and transfection to tumor cells
Total RNA of ACHN was isolated by the acid-guanidium thiocynate-phenol-chloroform method (Chomczynski and Sacchi, 1987) . First-strand cDNA was synthesized from the total RNA from ACHN using oligo-dT primer and Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc., Gaithersburg, MD). The human bcl-2 cDNA was ampli®ed by PCR from the ACHN cDNA by the sense primer (5'-CTTTTAGATCTGGAAG-GATGGCGCACGCTGG-3') containing a BglII site (underlined) and the antisense primer (5'-AGGCATCTA-GACTTCACTTGTGGCTCAGATAGG-3') containing a XI site (underlined). PCR was performed with a Perkin Elmer Cetus Gene Amp PCR system 9600 (Norwalk, CT) in a 25 ml reaction volume for 35 cycles using rTth DNA polymerase (Perkin Elmer). Each cycle consisted of denaturation at 958C for 1 min, annealing at 608C for 1 min and extension at 728C for 1 min. The PCR fragments were double digested with BglII and XbaI, and then ligated into a pDR2 expression vector (CLONTECH Laboratories, Inc., Palo Alto, CA) (Murphy et al., 1992) . The correct sequence of a cloned fragment was con®rmed by DNA sequence.
The pDR2/bcl-2 construction was transfected KoTCC-1 cells by the liposome-mediated gene transfer method (Felgner et al., 1987) . Brie¯y, 2610
5 KoTCC-1 cells were plated in a 6-cm dish 1 day before transfection. Five mg of puri®ed PDR2/bcl-2 or pDR2 (as a control) was added to KoTCC-1 cells after a preincubation for 30 min with 5 mg of lipofectamine reagent and 3 ml of serum-free OPTI-MEM (Life Technologies, Inc.). Drug selection, in 300 mg/ml Hygromycin (WAKO Pure Chemical Co., Osaka, Japan), was begun 3 days after transfection. Two weeks after the drug selection, colonies were harvested with cloning cylinders and expanded to cell lines.
Adenovirus vectors
Three previously described replication-de®cient recombinant adenovirus vectors (Zhang et al., 1993; Kanegae et al., 1995) were used in this study. Ad5CMV-p53 expresses the wild-type human p53 under the control of the human cytomegarovirus promoter, and Ad5CMV-Luc encoding Luciferase gene was used as a control vector. In addition, AxCALacZ encoding b-galactosidase gene was used to evaluate the eciency of the adenoviral-mediated gene transfer.
Adenoviruses were propagated in 293 cells, a human embryonic kidney cell line, which contains E1 and is thus highly permissive of the replication of the E1 replicationde®cient adenovirus. It was stored as previously reported. The viral infection titers were determined by plaque assays (Graham and Prevec, 1991) .
Examination of in vitro adenoviral transduction
To examine the in vitro infectious eciencies of the KoTCC-1 sublines with adenovirus, the cells were infected with Ad5CMV-LacZ (100 PFU/cell) for 24 h in the serumfree culture medium. Forty-eight hours after infection, the cells were washed twice with PBS and ®xed with 1 : 10 diluted formaldehyde for 10 min. The cells were then washed twice with PBS and stained with X-gal (Life Technologies, Inc.) for 12 h at 378C. The infectivities were quantitated by counting the percentage of blue cells.
Western blotting
The expression of Bcl-2 protein in the KoTCC-1 sublines and that of p53 protein after the treatment with cisplatin (10 mg ml 71 ) or the infection of adenoviral vectors (100 PFU/cell) was examined by Western blot analysis. Samples containing equal amounts of protein (15 mg) from lysates of the various cultured cells were electrophoresed on a 12% SDS-polyacrylamide gel and transferred to a nitrocellulose ®lter with a constant current of 140 mA for 2 h. The ®lters were blocked in PBS containing 10% nonfat milk powder at 48C overnight and then incubated for 1 h with a 1 : 200-diluted 6C8, an anti-human Bcl-2 hamster monoclonal antibody (BIOMOL Research Laboratories Inc, Plymouth Meeting, PA), 1 : 10000-diluted MAB065, an anti-rat b-tubulin mouse monoclonal antibody (CHEMI-CON INTERNATIONAL Inc., Tumecula, CA) that reacts with b-tubulin from all species (plant to human) or with 1 : 400-diluted 421 and 1801, anti-human p53 mouse monoclonal antibodies (Oncogene Science, Inc, Manhasset, NY) in PBS containing 0.03% Tween 20, and washed 3 times for 7 min each time with PBS containing 0.3% Tween 20. The ®lters were then incubated for 40 min with horseradish peroxidase-conjugated anti-hamster IgG antibody (ICN Inc, Costa Mesa, CA) for anti-Bcl-2 antibody and anti-mouse IgG antibody (Amersham Life Science, Arlington Heights, IL) for anti-p53 antibodies, and speci®c proteins were detected using an enhanced chemiluminescence Western blotting analysis system (Amersham Life Science).
MTT assay
The growth inhibitory eects of cisplatin and Ad5CMV-p53 on the KoTCC-1 sublines were assessed by MTT assay as described previously (Park et al., 1987) . Brie¯y, 1610 4 cells of each cell line were seeded in each well of 96-well microtiter plates and allowed to attach overnight. The next day, the medium was replaced with serum-free conditioned medium (DMEM/F-12) containing various doses of either cisplatin or Ad5CMV-p53. After 72 h of incubation, 20 ml of 5 mg/ml MTT (Sigma Chemical Co., St. Louis, MO) in PBS was added to each well, followed by incubation for 4 h at 378C. The formazan crystals were dissolved in dimethyl sulfoxide. The optical density was determined with a microculture plate reader (Becton Dickinson Labware, Lincoln Park, NJ) at 540 nm. Absorbance values were normalized to the values obtained for the vehicle-treated cells to determine the value for % of survival. Each assay was performed in triplicate. The IC 50 values were the drug concentrations inducing a 50% reduction in the optical density.
Flow cytometric analysis
The¯ow cytometric analysis of propidium iodide-stained nuclei was performed as previously reported (Kim et al., 1992) . Brie¯y, KoTCC-1 sublines were plated at a density of 5610 6 cells in 6-cm dishes. Twenty-four hours after plating, the medium was replaced with serum-free conditioned medium (DMEM/F-12) containing either cisplatin (10 mg ml 71 ) or Ad5CMV-p53 (100 PFU/cell). The cells were trypsinized after 72 h of incubation, washed twice with PBS and ®xed in 70% ethanol for 5 h at 48C. The ®xed cells were washed twice with PBS, incubated with 1 mg ml 71 RNase plus (Sigma Chemical Co.) for 1 h at 378C and stained with 5 mg ml 71 propidium iodide (Sigma Chemical Co.) for 1 h at room temperature. The stained cells were analysed for relative DNA content on a FACScan TM (Becton Dickinson Labware).
DNA fragmentation analysis
The nucleosomal DNA degradation was analysed as described previously (Armstrong et al., 1992) with a minor modi®cation. Brie¯y, 1610 5 cells of each cell line were seeded in 60 mm 2 culture dish and allowed to adhere overnight. The medium was then replaced with serum-free conditioned medium (DMEM/F12) containing either cisplatin (10 mg ml 71 ) or Ad5CMV-p53 (100 PFU/cell). After 72 h of incubation, the harvested cells were lysed in a solution containing 100 mM NaCl, 10 mM Tris (pH 7.4), 25 mM EDTA, and 0.5% SDS. After the centrifugation, the supernatants were incubated with 300 mg/ml proteinase K for 3 h at 508C and extracted with phenol-chloroform. The aqueous layer was treated with 0.1 volume of 3M sodium acetate, and the DNA was precipitated with a 2.5 volume of 95% ethanol. Following treatment with 100 mg/ ml RNase A for 1 h at 508C, the sample was loaded in a 2% agarose gel and stained with ethidium bromide.
Animal studies
Athymic nude mice (Balb/c nu/nu male, 6 ± 8 weeks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan) and housed in a controlled environment at 228C on a 12 h light, 12 h dark cycle. Each experimental group consisted of 5 mice.
The eects of the treatment with cisplatin and with Ad5CMV-p53 on tumor growth in vivo was assessed in tumor-bearing nude mice. The KoTCC-1 sublines were trypsinized, washed twice with PBS, and 5610 6 cells of each cell line was then injected subcutaneously in the right ank of nude mice. Three days after the implantation of tumor cells, 100 ml of cisplatin (5 mg kg
71
) was injected intraperitoneally twice a week for 2 weeks, and 7 days after the implantation, 300 ml of Ad5CMV-p53 (2610 7 PFU ml 71 ) was injected intratumorally twice a week for 2 weeks. The growth of the subcutaneous tumor was then successively measured with a caliper. The greatest length of a tumor mass (a) and the width perpendicular to it (b) were measured every 5 days, and the tumor size was reported as a6b.
The ecacies of the treatments with cisplatin and Ad5CMV-p53 were evaluated using the intraperitoneal tumor cell implantation model. Nude mice were injected intraperitoneally with 5610 6 cells of each cell line prepared as described above. Three days after the inoculation of tumor cells, the mice received intraperitoneally either 100 ml of cisplatin (5 mg kg 71 ) or 300 ml of Ad5CMV-p53 (2610 7 PFU ml 71 ) twice a week for 2 weeks. The survival of the mice was routinely observed, and the properties of ascites were examined when the mice died.
TUNEL staining
Three days after the same treatment schedules of cisplatin and Ad5CMV-p53 as described above was over, the terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine 5'-triphosphate nick end labeling (TUNEL) staining of the subcutaneous tumors in nude mice was performed. Frozen sections (6 mm) of tumor tissues were ®xed in 10% buered formarin for 15 min. After three washes in PBS, endogenous peroxidase was quenched with 2% H 2 O 2 for 5 min at room temperature and sections were washed twice in PBS. Labeling of 3'-OH-fragmented DNA ends was performed with an apoptosis in situ detection kit (WAKO, Osaka, Japan) following the manufacturer's instructions. We detected labeled ends with kit-supplied antibody to digoxigenin peroxidase and visualized using diaminobenzidene substrate. The sections were then counterstained with hematoxylin and mounted.
Statistical analysis
Survival data in the intraperitoneal tumor cell implantation model were analysed by the Kaplan-Meier technique using the generalized Wilcoxon test. All other data were evaluated by the Student's t test. The level of signi®cance was set at P50.05.
